PRODUCT NAME:
S100-β Determination Kit（Fluorescence Immunochromatography Assay）
Abbreviation: S100-β
INTENDED USE：
S100-β Determination Kit is an in vitro diagnostic test for the quantitative
detection of S100-β in human serum and plasma specimens.
With the increase of age, the incidence of stroke increases significantly.
Cerebrovascular disease is a serious threat to human health due to its high
morbidity, high mortality, and high disability rate. Stroke patients are often
accompanied by neurological dysfunctions of varying degrees, such as aphasia,
hemiplegia, and mental decline, which seriously affect the quality of life of
patients and increase the economic burden on society and families. It is
currently one of the most common death reasons of the elderly. Therefore,
research on the prevention and treatment of cerebrovascular disease has high
clinical application value and broad application prospects and is currently a
hot research topic in the international academic community. The relationship
between S100-β protein and cerebrovascular disease has become the focus of
attention in recent years. The study found that S100-β protein, as a biochemical
marker of damage to the new nervous system, is currently considered to be the
specific protein that can best reflect the degree and prognosis of brain damage.
Therefore, S100-β is used to judge the occurrence, development and prognosis
of acute cerebrovascular disease, and provide a theoretical basis for the early
diagnosis and treatment of cerebrovascular disease. There are many detection
methods for S100-β protein (S100-β), depending on the characteristics of the
detected substances and the substances bound to the antigen-antibody complex,
the commonly used methods are chemiluminescence immunoassay, colloidal
gold assay, and immunochromatography assay.
S100-β Determination Kit is a rapid, specific, and simple quantitative
detection kit established by solid phase immunochromatography technology.